Invatin Technologies
Continuous Stroke-prevention Device for High-risk Patients
Company Overview
Snapshot
Founded in March 2016 by Dr. Udi Nussinovitch, Invatin Technologies operated with 1–10 employees. The company secured funding across one round from one investor. In March 2022, Invatin Technologies ceased to operate.
Business overview
Invatin Technologies developed SYNAXIS-XT, an aortic arch uni-axial diverter designed to provide embolic protection to the three arteries ascending from the aortic arch. This technology aims to minimize the risk of cerebral ischemic stroke in high-risk patients by creating a mechanical barrier that redirects emboli away from the brain, while preserving blood flow and maintaining stent patency. The company operated within the Health Tech & Life Sciences sector, focusing on medical devices and medical treatment & therapeutics for healthcare providers and patients.
Log in to access full profile ›Company Intelligence Q&A
- What is SYNAXIS-XT?
- SYNAXIS-XT is an aortic arch uni-axial diverter developed by Invatin Technologies. It is designed to deliver embolic protection to the three arteries ascending from the aortic arch, minimizing the risk for cerebral ischemic stroke.
- What is the primary function of Invatin Technologies' device?
- The company's device provides a mechanical barrier, redirecting emboli away from the brain while preserving blood flow patterns and maintaining uncompromised stent patency. This technology helps prevent stroke in high-risk patients.
- When did Invatin Technologies cease operations?
- Invatin Technologies ceased to operate in March 2022.
- Who is a founder of Invatin Technologies?
- Dr. Udi Nussinovitch is a founder of Invatin Technologies, serving as the Founder & CSO.
- What was the status of Invatin Technologies' product development?
- Invatin Technologies' product, SYNAXIS-XT, was in the R&D stage. A feasibility study on the novel embolic protection device was published in November 2019, indicating ongoing development and research.